Publication details
Imunoonkoterapie u pacientek s onkogynekologickými nádory
| Title in English | Immuno-oncotherapy in patients with oncogynaecological tumours |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Onkologická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://onkologickarevue.cz/cs/imunoonkoterapie-u-pacientek-s-onkogynekologickymi-nadory |
| Keywords | gynecologic oncology; cancer immunotherapy; monoclonal antibodies; biosimilars; antibody-drug conjugates; immune checkpoint inhibitors.; |
| Description | The landscape of cancer immunotherapy for gynecologic malignancies is wide, complex and unstructured. The aim of this review article is to summarize updated results of clinical trials of all types of cancer immunotherapy (monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors) and to discuss current applications and future perspectives. Immunooncology has been difficult to utilize in ovarian cancer due to extremely tumor suppressive microenvironment, low number of tumor-infiltrating lymphocytes, low presence of microsatellite instability when compared to cervical and endometrial carcinoma. Strategies to overcome this include combining immunotherapy with conventional cytotoxic drugs. The history of immunotherapy in gynecological malignancies begins with Bacillus Calmette-Guerin in the 1970s, followed by bevacizumab and more recently several novel immunological based compounds (oregovomab is also being tested in first-line systemic combination therapy for ovarian cancer in phase III clinical trials). Checkpoint inhibition alone has been effective in endometrial and cervical cancer. More recently the combination of pembrolizumab and lenvatinib in advanced and recurring endometrial carcinoma has shown profound response even in microsatellite instability-high subtypes. Pembrolizumab has been utilized in PD-L1 positive cervical carcinoma and other checkpoint inhibitors are being combined with CTLA-4 antibodies in ongoing clinical trials globally. These results are reflected in updated guidelines of the Czech Society for Oncology. |